Novartis
ProfileJobs

Novartis

Suggest Edit
    • Healthbiotechclinical researchdrug developmentmanufacturerpharma

    Novartis is a global healthcare company that provides solutions to address the evolving needs of patients worldwide. The Company's businesses are divided into three operating divisions: Pharmaceuticals, Alcon (eye care) and Sandoz (generics). Novartis manufactures the drugs clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan) and imatinib mesylate (Gleevec/Glivec). Additional agents include ciclosporin (Neoral/Sandimmun), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil) and others. The Company is one of the largest pharmaceutical companies by both market cap and sales.



    Show more
    Revenue(FY, 2016)
    $48.5 B
    Type
    Public
    Parent Company
    GlaxoSmithKline
    HQ
    Basel, CH
    Founded
    1996
    Size (employees)
    126,000 (est)+5%
    Website
    novartis.com
    Novartis was founded in 1996 and is headquartered in Basel, CH
    Report incorrect company information

    Key People/Management at Novartis

    Vasant Narasimhan

    Vasant Narasimhan

    Chief Executive Officer of Novartis
    Steven Baert

    Steven Baert

    Head of Human Resources of Novartis
    Elizabeth Barrett

    Elizabeth Barrett

    CEO, Novartis Oncology
    Bertrand Bodson

    Bertrand Bodson

    Chief Digital Officer of Novartis
    James Bradner

    James Bradner

    President, Novartis Institutes for BioMedical Research (NIBR)
    Richard Francis

    Richard Francis

    CEO, Sandoz
    Show more

    Novartis Office Locations

    Novartis has offices in Basel, New York, East Hanover, Wehr and in 2 other locations
    Basel, CH (HQ)
    Forum 1, Novartis Campus
    Beijing, CN
    14th floor, China World Tower 2, No.1 Jian Guo Men Wai Avenue, Chao Yang District
    Wehr, DE
    Oeflingerstrasse 44
    Tokyo, JP
    Toranomon Hills, Mori Tower, 1-23-1, Toranomon, Minato-ku
    East Hanover, US
    1 Health Plazam, Bldg. 101
    New York, US
    230 Park Avenue, 21st Floor
    Show all (6)
    Report incorrect company information

    Novartis Financials and Metrics

    Novartis Revenue

    Embed Graph
    Novartis's revenue was reported to be $48.52 b in FY, 2016 which is a 1.8% decrease from the previous period.
    USD

    Revenue (FY, 2016)

    		48.5 b

    Revenue growth (FY, 2015 - FY, 2016), %

    		(1.8%)

    Gross profit (FY, 2016)

    		31 b

    Gross profit margin (FY, 2016), %

    		63.9%

    Net income (FY, 2016)

    		6.7 b
    USDFY, 2014FY, 2015FY, 2016

    Revenue

    		53.6 b49.4 b48.5 b

    Revenue growth, %

    		(8%)(2%)

    Cost of goods sold

    		17.3 b17.4 b17.5 b

    Gross profit

    		36.3 b32 b31 b
    show all
    USDFY, 2015FY, 2016

    Cash From Operating Activities

    		12.1 b11.5 b
    show all
    USDY, 2016

    Revenue/Employee

    		407.7 k
    Show all financial metrics

    Novartis Operating Metrics

    Y, 2015Y, 2016

    Major Approvals (US, EU, JP)

    		20 16

    Patients Reached

    		972 m965 m

    Phase III Trials Products

    		37 29

    Projects Entering Development Pipeline

    		8 5
    Show all operating metrics

    Novartis Acquisitions / Subsidiaries

    Acquired CompanyDateDeal Size
    Advanced Accelerator Applications October 30, 2017$3.90 b
    AveXis $8.70 b

    Novartis Revenue Breakdown

    Embed Graph

    Novartis revenue breakdown by business segment: 67.1% from Innovative Medicines, 20.9% from Sandoz and 12.0% from Alcon

    Report incorrect company information

    Competitors

    Kite Pharma
    Health - Subsidiary
    Bayer
    Health - Public
    Bristol-Myers Squibb
    Health - Public
    GlaxoSmithKline
    Health - Public
    AbbVie
    Health - Public
    Baxalta
    Health - Subsidiary
    Compare competitors

    Novartis Online and Social Media Presence

    Embed Graph
    Report incorrect company information

    Novartis News and Updates

    July 22, 2018

    Novartis: Transformation Continues

    July 20, 2018

    CAR T-Cell Therapy for Multiple Myeloma Market to witness astonishing growth by key players Juno Therapeutics, Kite Pharma, Novartis & Collectis

    CARs are also known as chimeric immunoreceptors, chimeric T-cell receptors, artificial T-cell receptors or CAR T. they are used as an individual's own cells and re-engineers them to fight cancer. Posted via Industry Today. Follow us on Twitter @IndustryToday
    July 20, 2018

    Mustang Bio: A Differentiated CAR-T Innovator With Multiple Unlocking Catalysts

    July 19, 2018

    Drug Giant Novartis Is Temporarily Backing Off Price Increases Following Trump Pressure

    But there's a catch.
    July 19, 2018

    Novartis nabs much-needed new nod for slow-growing breast cancer drug Kisqali

    Less than one day after Novartis CEO Vas Narasimhan talked up a potential key approval for lagging breast cancer drug Kisqali, the company has that approval in hand.
    July 19, 2018

    Pizotifen Industry : Research Analysis, Development Trends and Survey Report

    Pizotifen Industry report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa.On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into ,Pizotifen 0.5 mg Tab…
    Show more
    Report incorrect company information

    Novartis Company Life and Culture

    Report incorrect company information
    Download PDF